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Synthetic gene circuits for preventing
disruption of the circadian clock due to
interleukin-1–induced inflammation
Lara Pferdehirt1,2,3,4†, Anna R. Damato5†, Michal Dudek6, Qing-Jun Meng6,
Erik D. Herzog5, Farshid Guilak1,2,3,4*
The circadian clock regulates tissue homeostasis through temporal control of tissue-specific clock-controlled
genes. In articular cartilage, disruptions in the circadian clock are linked to a procatabolic state. In the presence of
inflammation, the cartilage circadian clock is disrupted, which further contributes to the pathogenesis of diseases such
as osteoarthritis. Using synthetic biology and tissue engineering, we developed and tested genetically engineered
cartilage from murine induced pluripotent stem cells (miPSCs) capable of preserving the circadian clock in the
presence of inflammation. We found that circadian rhythms arise following chondrogenic differentiation of miPSCs.
Exposure of tissue-engineered cartilage to the inflammatory cytokine interleukin-1 (IL-1) disrupted circadian rhythms
and degraded the cartilage matrix. All three inflammation-resistant approaches showed protection against IL-1–
induced degradation and loss of circadian rhythms. These synthetic gene circuits reveal a unique approach to support
daily rhythms in cartilage and provide a strategy for creating cell-based therapies to preserve the circadian clock.

The circadian clock is an internal genetic timing mechanism that
exists in the brain and nearly all cells in peripheral tissues, operating
on a roughly 24-hour period (1–3). The circadian clock coordinates
tissue-specific physiology with different cycles such as light and
darkness, body temperature, and rest and activity (1). The core clock
mechanism, composed of transcriptional activators, Bmal1 and
Clock, and transcriptional repressors, Per1/2 and Cry1/2, form an
autoregulatory negative feedback loop that drives rhythmic gene
expression. This transcription-translation feedback loop regulates
output genes, such as Rev-erbs, Dbp, and Nfil3 (2, 3). The circadian
clock drives expression of many other genes, referred to as clockcontrolled genes, that are tissue specific and play important roles
in maintaining tissue homeostasis through their temporal nature
(1, 4–6). Disruptions in the circadian clock and subsequent disruptions in expression of these clock-controlled genes have been linked
to several diseases such as obesity, diabetes, cardiovascular disease,
and osteoarthritis (OA) (2, 4, 7, 8).
Clock genes play a critical role in maintaining tissue homeostasis
in many different musculoskeletal tissues including muscle, tendon,
bone, and articular cartilage (4, 9). Articular cartilage consists of an
abundant extracellular matrix (ECM) synthetized by the only resident cell type, chondrocytes (10–12). Articular cartilage is avascular
and aneural and is maintained through a balance between anabolic
and catabolic activities. Disruption to this balance, for example,
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through increased inflammation, drives the degradation of articular
cartilage, which is a key characteristic of OA, the leading cause of
pain and disability worldwide (13–15). It has been shown that many
anabolic and catabolic pathways in articular cartilage have different
daily dynamics, driven by a functional circadian clock in chondrocytes, that help maintain cartilage homeostasis (4, 9, 16–23). Several
cellular functions exhibit time of day–dependent activity, including
metabolic, ECM remodeling, and catabolic pathways (4, 20), and
disruptions in the clock cause loss in rhythmic expression and altered
expression of these pathways (20). For example, the cartilage-specific
knockout (KO) of one of the core clock genes, Bmal1, results in a
catabolic response and cartilage degradation in mice (18). These
findings suggest that the disruption of the circadian clock in cartilage
could be an important contributor to the pathogenesis of OA (24).
Inflammation is a key driver in the pathogenesis of OA, characterized by increased levels of proinflammatory cytokines such as
interleukin-1 (IL-1) and tumor necrosis factor– (TNF), which, in
turn, induce ECM degradation through the enhanced production
of degradative enzymes and other proinflammatory mediators that
shift chondrocyte activity to a procatabolic state (25–29). Inflammation has been shown to disrupt circadian rhythms in cartilage
(30). The addition of IL-1 to cartilage explants caused a loss in
circadian rhythms that was only rescued with the administration of
dexamethasone (dex), an anti-inflammatory agent (30). Anticytokine
therapies such as IL-1 receptor antagonist (IL-1Ra; anakinra) have
shown promise in alleviating symptoms of posttraumatic OA (31–33);
however, systemically delivered anticytokine therapies are administered at high doses, which may have off-target effects, including an
increased susceptibility to infection and certain autoimmune diseases (34) as well as limited tissue regeneration and repair (35–37).
Because of the drawbacks with anticytokine therapies and lack
of effective disease-modifying treatments to address both the symptoms and structural changes of OA (38–40), we used genetic engineering to develop various self-regulating cellular systems to address
these limitations (41). Using CRISPR-Cas9 gene editing, we created
murine induced pluripotent stem cells (miPSCs) lacking a functional
1 of 11

Downloaded from https://www.science.org at Washington University on June 05, 2022

INTRODUCTION

Copyright © 2022
The Authors, some
rights reserved;
exclusive licensee
American Association
for the Advancement
of Science. No claim to
original U.S. Government
Works. Distributed
under a Creative
Commons Attribution
NonCommercial
License 4.0 (CC BY-NC).

SCIENCE ADVANCES | RESEARCH ARTICLE

Fig. 1. Inflammation-resistant cell-based therapies and circadian measurements. Tissue-engineered cartilage pellets with a circadian reporter (P2L) were
tracked to measure their circadian clock. (A) Schematic of the molecular circadian
transcription-translation feedback loop. (B) In the presence of IL-1, the circadian
clock was disrupted. Three different genetic engineering–based cell therapies
were developed to be resistant to IL-1: (C) IL1R1 KO, CRISPR-Cas9–edited cells
lacking the IL1R1; (D) Ccl2-IL1Ra, CRISPR-Cas9–edited cells that produce an IL-1
antagonist, IL-1Ra, in response to inflammation and subsequent expression of Ccl2;
and (E) NFBr-IL1Ra, lentiviral gene therapy circuit with a synthetic promoter activated
by NF-B signaling driving production of IL-1Ra. The ability of these cell therapies
to preserve the circadian clock in the presence of inflammation was tested.

IL-1 receptor 1 (IL1R1) that can successfully be differentiated into
tissue-engineered cartilage that is protected from IL-1–induced matrix
degradation (IL1R1 KO) (42). We also used CRISPR-Cas9 gene editing in miPSCs to incorporate IL-1Ra, a competitive antagonist of
IL-1, downstream of the Ccl2 locus (Ccl2-IL1Ra) to drive controlled
production of IL-1Ra in response to inflammation and subsequent
activation of Ccl2 (43). These cells were also able to protect cartilage
from inflammation-mediated degradation (43). Furthermore, we have
also developed a synthetic promoter that is activated by nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-B) to drive
production of our desired transgene, IL-1Ra (NFBr-IL1Ra) (44). The
NF-B signaling pathway is a key inflammatory pathway in articular
cartilage that is activated by various cytokines such as IL-1, leading to
the up-regulation of other proinflammatory mediators. This lentiviral
gene therapy has been shown to inhibit IL-1 in response to inflammation or mechanical loading in miPSC-derived tissue-engineered
cartilage and also in primary porcine chondrocytes (44, 45).
Because of the critical role of the circadian clock in maintaining
cartilage tissue homeostasis, as evidenced by altered gene expression
(20) and cartilage degradation (18) caused by disruptions in circadian
rhythms, and the recent finding that inflammation can drive disruption in the chondrocyte circadian clock, the goal of this study was to
Pferdehirt et al., Sci. Adv. 8, eabj8892 (2022)
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RESULTS

The circadian clock develops in miPSCs with each stage
of chondrogenesis
To assess the development of circadian rhythms during chondrogenesis, we transduced miPSCs and predifferentiated iPSCs (PDiPSCs)
with Per2-Luc (P2L) or Bmal1-Luc (B1L) lentivirus and tracked the
bioluminescence output of miPSCs, PDiPSCs in monolayer, PDiPSCs
freshly cast in agarose, and chondrogenic cartilage pellets (Fig. 2A).
We found that miPSCs expressed P2L and B1L, but with no evidence
of circadian oscillation (e.g., periods >32 hours; Fig. 2B). In addition,
at the PDiPSC differentiation stage, P2L-transduced PDiPSCs began to oscillate (average period = 28.1 ± 3.1 hours, means ± SEM),
and B1L oscillation, which appears after Per2 expression in development (46), had not yet occurred (period length >32 hours; Fig. 2B).
However, PDiPSCs cast in a three-dimensional (3D) agarose system
showed enhanced rhythmicity in Per2 (average period = 26.3 ±
2.2 hours), while Bmal1 remained arrhythmic (period length >32 hours;
Fig. 2B). Tissue-engineered cartilage pellets showed high amplitude
oscillations of Per2 and Bmal1 in antiphase, indicating the circadian
clock had fully developed in our tissue-engineered cartilage (P2L
period = 23.2 ± 3.1 hours, B1L period = 21.5 ± 4.9 hours; Fig. 2B).
Murine cartilage explants were taken from the femoral head
of 10-week-old homozygous PER2::LUC mice (5). Bioluminescence
recording of these cartilage explants demonstrated sustained circadian rhythms, as shown previously (Fig. 2C). Our tissue-engineered
cartilage pellets had similar period length compared with PER2::LUC
oscillations in the cartilage explants, further confirming the development and maturation of the circadian clock in our tissue-engineered
cartilage (engineered cartilage period = 23.2 ± 3.1 hours, explant
period = 23.9 ± 1.5 hours). In addition, we transduced primary
porcine chondrocytes with our P2L lentivirus, and these porcine
chondrocytes also showed sustained daily oscillations similar to our
2 of 11
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develop tissue-engineered cartilage with genetically engineered
stem cells to preserve the circadian clock in response to inflammation (Fig. 1). Therefore, we sought to establish a platform for testing
the role of circadian rhythms in cartilage maintenance and accomplished this by first testing when circadian rhythms arise while differentiating our miPSCs into chondrocytes and then the consequences
of inflammatory signals on chondrocyte circadian rhythms and cartilage integrity, before testing the ability of our genetically engineered circuits to preserve circadian rhythms. However, note that
undifferentiated stem or progenitor cells generally do not exhibit
circadian rhythms (46). Therefore, we first tested the hypothesis that
circadian rhythms and cartilage matrix develop together as a part of
chondrogenic differentiation in miPSCs. We next determined the
effect of inflammatory cytokines on circadian cycling in our tissueengineered pellets and determined that IL-1 and IL-1, but not
TNF, drive disruptions in circadian rhythm. We then tested the
ability of our genetically engineered cell-based therapies targeting
IL-1 to protect the clock from IL-1–induced disruption. We show
the ability of our self-regulating synthetic gene circuits to preserve
daily rhythmicity and protect against inflammation-mediated disruption and cartilage degradation. These findings further our understanding of the circadian rhythm coordination in cartilage and its
disruption in response to inflammatory cytokines and introduce the
concept of a “clock-preserving” mechanism through the combination
of synthetic biology and tissue engineering of stem cell gene circuits.
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tissue-engineered pellets (period = 23.5 ± 3.3 hours; Fig. 2D). Together, these findings indicate that as murine iPSCs undergo chondrogenesis in tissue-engineered cartilage, they develop a circadian
clock that has high amplitude and sustained oscillations, similar to
that of primary chondrocytes or mature cartilage in another species.
Inflammation disrupts the circadian clock in native
and tissue-engineered cartilage
We next examined the effects of inflammatory cytokines IL-1, IL1, and TNF on circadian rhythms in tissue-engineered cartilage
pellets. It has previously been shown that IL-1 causes disruption in
the circadian rhythms of murine cartilage explants through loss in
bioluminescence oscillations and changes in clock gene expression;
however, TNF had no effect (30). For these studies, we treated mature tissue-engineered cartilage transduced with the P2L lentiviral
reporter with pathophysiologic levels of cytokines, IL-1 (1 ng/ml),
IL-1 (1 ng/ml), TNF (20 ng/ml), or phosphate-buffered saline
(PBS) as a control. Bioluminescence tracking of P2L was recorded
for 3 days before addition of cytokines. Cytokines were added in 2-l
volumes, and pellet bioluminescence was tracked for an additional
3 days after cytokine addition. To determine the effect of these
Pferdehirt et al., Sci. Adv. 8, eabj8892 (2022)
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Fig. 2. Development of the circadian clock in miPSC chondrogenesis. (A) Differentiation protocol of miPSCs to chondrocytes. miPSCs were subjected to highdensity micromass culture to create PDiPSCs. PDiPSCs were then either cast in agarose
or pelleted and cultured in chondrogenic media for 14 to 21 days to create tissueengineered cartilage. (B) P2L bioluminescence intensity (BLI) of miPSCs (n = 10),
PDiPSCs (n = 2), PDiPSCs in agarose (n = 4), and pellets (n = 10) (left) and B1L bioluminescence intensity (BLI) of miPSCs (n = 5), PDiPSCs (n = 4), PDiPSCs in agarose
(n = 5) (middle), and pellets (n = 5) (right). (C) BLI of femoral head cartilage explants
from PER2::LUC mice (n = 3, one hip per mouse). (D) P2L BLI in porcine chondrocytes
cast in agarose (n = 5). Shaded region on graphs represents SEM.

cytokines on circadian rhythms, we analyzed both the period and
decrease in amplitude, as these are considered the primary markers
of circadian disruption. Decreased amplitude represents decreased
oscillation in clock gene expression and weakening of circadian
rhythms. Pellets subjected to inflammatory challenge were also collected for histological and biochemical analysis of a main component
of articular cartilage, sulfated glycosaminoglycans (sGAGs), and
analyzed for up-regulation of inflammatory genes Il6 and Ccl2. Histological and biochemical analysis of sGAG was performed to determine the effect of cytokines on cartilage matrix after addition of
cytokine, with sGAG staining and concentration providing a sensitive measure of cytokine-induced cartilage matrix degradation. Before cytokine addition, all pellets showed circadian oscillations of
P2L (n = 46; Fig. 3A). Pellets treated with PBS maintained circadian rhythms to the end of the recording (n = 20, pre-PBS period =
25.4 ± 3.1 hours, post-PBS period = 25.6 ± 7.2 hours; Fig. 3A) and
exhibited a daily decrease in amplitude, seen in in vitro cultures,
similar to undisturbed control pellets (fig. S1). Pellets treated with
TNF also continued to maintain circadian oscillations (n = 7, five of
the seven were rhythmic after treatment, post-TNF period = 27.6 ±
3.8 hours; Fig. 3A). Pellets treated with IL-1 showed a lengthening
of period in all pellets (n = 8, six of the eight were rhythmic after treatment, post-IL1 period = 29.5 ± 4.6 hours; Fig. 3A). In contrast, pellets
treated with IL-1 showed a rapid loss in circadian rhythms (n = 11,
6 of the 11 were rhythmic after treatment, post-IL1 period = 31.7 ±
6.6 hours; Fig. 3A) and decreased bioluminescence amplitude (P = 0.037;
Fig. 3B). Nonnormalized, representative traces from each treatment
group exhibited individual variability in mean bioluminescence, which
justifies the display of normalized group-level data (fig. S2). However, all amplitude and period measurements were made from nonnormalized traces. Cartilage explants from PER2::LUC mice were also
subjected to inflammatory challenge, and the bioluminescence output was recorded (Fig. 4). Similar to our tissue-engineered cartilage
pellets, TNF had no effect on the circadian rhythm of the cartilage
explants; however, both IL-1 and IL-1 given at 1 ng/ml showed a
rapid loss in circadian rhythms compared with controls and significant decrease in amplitude compared with PBS controls (P = 0.0021
and 0.0005, respectively; Fig. 4). The induction of PER2 bioluminescence that can be observed in all groups, including PBS treated, is a
commonly observed phenomenon resulting from the role of PER2 in
cellular stress response and regulation of mammalian target of rapamycin
(mTOR), a cellular growth pathway (47, 48).The similar expression
of circadian rhythms and responses to inflammatory cytokines of our
tissue-engineered cartilage and ex vivo cartilage explants supports
their utility as an in vitro model system.
To better understand the effect of each cytokine on circadian
rhythm and begin to elucidate the functional outputs of the cartilage clock, we examined the effect of cytokines on the degradation
of cartilage ECM, since the circadian clock is known to maintain
cartilage homeostasis (4, 9, 16–20). Pellets were stained with safranin
O to look at sGAG content (n = 4 per group; Fig. 3C). In addition,
sGAG content within pellets was quantified by biochemical analysis
and normalized to DNA content within each pellet (n = 4 per group;
Fig. 3D). The staining for sGAG showed rich red stain in the PBS
control pellets and the pellets treated with TNF, while pellets treated
with IL-1 showed reduced sGAG staining, and pellets treated with
IL-1 showed a loss in sGAG (Fig. 3D). The quantification of sGAG
content matched the histological images, where the TNF-treated
pellets had similar sGAG content compared with PBS controls,

SCIENCE ADVANCES | RESEARCH ARTICLE

whereas the IL-1– and IL-1–treated pellets showed significant
sGAG loss compared with PBS controls (P < 0.0001; Fig. 3D).
Last, inflammatory genes Il6 and Ccl2 were examined in pellets
treated with cytokines. IL-6 is a cytokine that up-regulates inflammatory pathways within the joint, and CCL-2 is a chemokine that
attracts immune cells to the joint. While treatment of pellets with
TNF significantly up-regulated Ccl2 gene expression compared with
PBS controls (n = 4, P = 0.0002), it did not significantly affect Il6
expression (n = 4; Fig. 3E). Addition of IL-1 and IL-1 significantly
increased Ccl2 expression compared with PBS controls (n = 4,
Pferdehirt et al., Sci. Adv. 8, eabj8892 (2022)
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P = 0.0086 and 0.0122, respectively), as well as Il6, especially in the
pellets treated with IL-1 (n = 4, P < 0.0001 for both IL-1 and
IL-1; Fig. 3E). These data also suggest that, although up-regulation
of chemokines such as Ccl2 for immune cell recruitment is important, cytokines such as IL-1 and IL-6 are more likely to be involved
in the disruption of circadian timing. Together, this suggests that
inflammatory cytokines IL-1 and IL-1 can disrupt the cartilage
circadian clock in cartilage explants and our tissue-engineered cartilage,
and this effect might be through the up-regulation of inflammatory
cytokines, such as IL-6, that lead to matrix degradation.
4 of 11
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Fig. 3. Tissue-engineered cartilage response to inflammatory cytokines. (A) P2L bioluminescence traces of pellets pre and post cytokine [TNF (n = 7), IL-1 (n = 8),
IL-1 (n = 11), or PBS (n = 20)]. Tissue-engineered cartilage pellets were treated with TNF, IL-1, IL-1, or PBS control for 72 hours. Bars show addition of cytokine or PBS
control. Shaded region on graphs represents SEM. (B) P2L pellets treated with IL-1 show rapid decrease in bioluminescence followed by lower-amplitude circadian
rhythm (P = 0.037). The amplitude due to treatment was quantified by measuring the difference in peak-trough amplitude 24 hours before and 48 hours following treatment. Asterisks represent significance compared with PBS control. (C) Safranin O staining for sGAGs (n = 4 per treatment; scale bar, 100 M). Pellets treated with IL-1 and
IL-1 show loss in stain. (D) Quantification of sGAGs normalized to DNA content within each pellet (n = 4 per treatment). Pellets treated with IL-1 and IL-1 show significant loss in sGAG compared with PBS controls (P < 0.0001). Asterisks represent significant differences as compared with PBS controls. (E) Gene expression analysis of
Il6 and Ccl2 (n = 4 per treatment, fold change relative to PBS control). Only IL-1 and IL-1 treatment caused up-regulation of Il6 (P = 0.0002). All cytokine treatments
caused up-regulation in Ccl2 (P < 0.05). Asterisks represent significant differences as compared with PBS controls.
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IL-1–resistant genetically engineered tissues are resistant
to circadian disruption
Cartilage explants treated with IL-1 and IL-1 recovered the loss
in circadian rhythms with the addition of dex, an anti-inflammatory agent (Fig. 4). Previously, it has been shown that forskolin, a circadian rhythm synchronizer, could not recover circadian rhythms
in cartilage explants treated with cytokines and that only the administration of an anti-inflammatory agent could recover circadian
disruptions due to inflammation (30). We therefore sought to test
whether our anti-inflammatory cell therapies could preserve circadian
cycling in the presence of IL-1. For these studies, we used three cell
lines designed to blunt the response to inflammation through different mechanisms (Fig. 5A). To test whether IL-1 acts through
IL1R1 to disrupt circadian rhythms, we used miPSC CRISPR-Cas9
edited without IL1R1 (IL1R1 KO) (42). miPSCs edited with CRISPRCas9 to incorporate IL-1Ra downstream of the Ccl2 locus (Ccl2-IL1Ra)
(43) allowed us to study the impact of endogenous circuit activation
with rapid activation kinetics capable of inhibiting IL-1–mediated
inflammation. A lentiviral circuit incorporating a synthetic promoter
activated by the NF-B signaling pathway that drives production of
IL-1Ra (NFBr-IL1Ra) (44) allowed us to study the impact of a synthetic activation system with increased IL-1Ra production compared
with our Ccl2-IL1Ra system. All the miPSC lines or miPSCs were
transduced with the lentiviral vector containing the P2L reporter
and differentiated into tissue-engineered cartilage pellets. We then
treated with IL-1 and assessed the ability of these pellets to maintain cartilage integrity and circadian expression.
We found that all groups (P2L controls, IL1R1 KO, Ccl2-IL1Ra,
and NFBr-IL1Ra) had no baseline difference in IL-1Ra production
(n = 10 per group; Fig. 5B). P2L and IL1R1 KO pellets also showed
Pferdehirt et al., Sci. Adv. 8, eabj8892 (2022)
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no difference in IL-1Ra production when treated with IL-1 (1 ng/
ml). Both Ccl2-IL1Ra and NFBr-IL1Ra had significantly increased
IL-1Ra production in response to IL-1 (1 ng/ml), with the
NFBr-IL1Ra producing the highest amount of IL-1Ra (n = 10 per
group, Ccl2-IL1Ra ~36 ng/ml IL-1Ra, NFBr-IL1Ra ~74 ng/ml
IL-1Ra, P < 0.0001).
After confirming that our self-regulating cells were producing sufficient IL-1Ra to inhibit IL-1 activity, we next tracked P2L
through bioluminescence before the addition of cytokine and for
3 days after addition of IL-1 (1 ng/ml). All four groups before the
addition of cytokine were rhythmic, showing that the process of gene
editing did not disrupt the clock (n = 13, pre–IL-1 period = 24.6 ±
2.9 hours; Fig. 5C). All three of our cell therapy groups showed
maintained circadian rhythms in response to IL-1 (n = 13, post–
IL-1 period = 24.4 ± 2.0 hours; Fig. 5C), whereas the nonengineered
controls became arrhythmic (n = 12; Fig. 5C). Cytokine-treated resistant pellets showed a decrease in amplitude comparable to what
we observed in PBS-treated control pellets, which occurs naturally
in culture in the absence of entraining cues (Fig. 5D). The three
engineered systems all protected the cells from the cytokine-induced
decreases in circadian rhythmicity, such that there were no significant changes in the fraction of circadian cultures, their period, or
their amplitude compared with control cultures.
In addition, when examining staining and quantification of sGAG
content of the cartilage ECM, the IL1R1 KO, Ccl2-IL1ra, and NFBrIL1Ra groups exhibited rich safranin O staining and no difference
in sGAG content between control pellets (no cytokine treatment)
and pellets treated with IL-1 (1 ng/ml) compared within each cell
therapy group (n = 4 to 6 per group for histology, n = 8 to 10 per
group for biochemical analysis; Fig. 5, E and F). Last, we found that
5 of 11
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Fig. 4. Cartilage response to inflammatory cytokines. Per2 expression in cartilage explants from the femoral head of PER2::LUC mice was recorded as bioluminescence
intensity. Explants were treated with IL-1 (1 ng/ml), IL-1⍺ (1 ng/ml), TNF⍺ (20 ng/ml), or vehicle controls (n = 3 per each condition). Loss of circadian rhythm was seen in
explants, given IL-1 and circadian rhythm was rescued with the administration of dex. Gray, blue, orange, and red bars indicate administration of PBS or cytokine; black
bars indicate administration of dex. Shaded region on graph represents SEM. Asterisks represent significance compared to controls (P < 0.05). **P < 0.01; ***P < 0.05.
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the induction of Il6 by IL-1 (1 ng/ml) was markedly reduced in all
engineered cell groups (n = 6 to 8, P < 0.0001; Fig. 5G), and induction of Ccl2 was blocked (n = 6 to 8, P < 0.0001; Fig. 5G). The partial
blockade of IL-1 effects on Il6 72 hours after treatment in the
Ccl2-IL1Ra group compared with other treatments (n = 6 to 8,
Pferdehirt et al., Sci. Adv. 8, eabj8892 (2022)
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P < 0.05; Fig. 5G) was consistent with the self-regulating response
that rapidly inhibits IL-1 signaling (43) and the lower production
of IL-1Ra. Together, these data demonstrate that our cell therapies
edited to either be nonresponsive to IL-1 (IL1R1 KO) or be selfregulating and produce an anti-inflammatory therapeutic, IL-1Ra,
6 of 11
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Fig. 5. Engineered cell therapy response to IL-1. (A) Three different anti-inflammatory cell therapies expressing a P2L reporter were used to test the ability to protect the
circadian rhythm of tissue-engineered cartilage: CRISPR-Cas9–edited miPSCs lacking the IL-1R (IL1R1 KO), CRISPR-Cas9–edited miPSCs that produce IL-1Ra downstream of the
Ccl2 promoter (Ccl2-IL1Ra), and a lentiviral gene therapy composed of an NF-B–responsive synthetic promoter that drives production of IL-1Ra (NFBr-IL1Ra). (B) IL-1Ra
concentration in response to IL-1 stimulation (n = 10 per group). The Ccl2-IL1Ra and NFBr-IL1Ra groups showed increased IL-1Ra production in response to IL-1. Different
letters denote groups that are significantly different. b compared to a (P < 0.002), c compared to a or b (P < 0.0001). (C) P2L bioluminescence traces of pellets before and after
cytokine (n = 13). All three cell therapy groups showed protection of the clock from IL-1–induced detrimental effects. Red bar represents addition of IL-1⍺. Shaded region on
graph represents SEM. (D) Change in amplitude due to treatment was quantified by measuring the difference in peak-trough amplitude 24 hours before and 48 hours following treatment and was similar to normal damping of rhythms observed in PBS-treated samples. (E) Safranin O staining for sGAGs (n = 4 to 6 per group; scale bar, 100 M).
(F) Quantification of sGAGs normalized to DNA content within each pellet (n = 8 to 10 per treatment). Cell therapy groups showed no significant loss in sGAG in response to
IL-1. Asterisks denote the significance compared to PBS control within group. n.s., not significant. (G) Gene expression analysis of Il6 and Ccl2 (n = 6 to 8 per group fold change
relative to P2L-untreated control). All cell therapy groups showed significantly less inflammatory gene expression compared with IL-1–treated controls. Different letters
denote groups that are significantly different. For Il6, b compared to a (P < 0.0045), and c compared to a or b (P < 0.0001). For Ccl2, b compared to a (P < 0.0001).

SCIENCE ADVANCES | RESEARCH ARTICLE
can effectively protect their cartilage ECM from degradation and preserve the circadian clock in the presence of IL-1.
DISCUSSION

Pferdehirt et al., Sci. Adv. 8, eabj8892 (2022)
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By combining tissue engineering, synthetic biology, and circadian
biology, we developed cell-based tissue constructs that are capable
of preserving the cartilage circadian clock in response to disruptive
stimuli such as IL-1–induced inflammation. While significant advances have been made in understanding the physiology of the circadian clock in recent years, the use of genetic approaches has not
been used previously to create cell-based clock-preserving therapeutic systems. Here, we used chondrocytes and tissue-engineered
cartilage as our model system, which provides a homogeneous cell
population that avoids the complexities of interpreting data from
multiple cell types. Using this system, we have been able to uncover
characteristics of cartilage circadian rhythms and established a robust system for peripheral clock studies. These types of tools can be
used to mitigate disease where circadian disruption plays a role (4),
can be used to create better engineered tissues by ensuring tissue
homeostasis through clock-controlled genes (4, 9), and may be used
to uncover important characteristics of the circadian clock not yet
known. In combination with tissue engineering, the use of genetically
modified cells may allow the formation of functional bioartificial
tissues with intrinsic clock-preserving characteristics.
In quantifying clock gene expression in miPSCs, we observed
that undifferentiated cells were not rhythmic and developed their
circadian timing over the course of chondrogenic differentiation.
This is consistent with prior reports that mouse embryonic stem
cells and other stem/progenitor cells cannot generate circadian
rhythms until they differentiate (46), suggesting that formation of a
mature circadian clock is an integral characteristic of cellular differentiation. We detected daily rhythms in Per2, but not Bmal1, in
PDiPSCs. Consistent with a prior report on clock development in
mouse embryonic cells (46), this finding may indicate the beginning
stages of rhythmogenesis and may reflect some limitations in the
ability to detect weak rhythms in Bmal1 with this system. Furthermore, we observed that iPSC-derived chondrocytes or primary porcine
chondrocytes in tissue-engineered cartilage pellets showed a similar
circadian response as primary murine cartilage and responded similarly to inflammatory cytokines, indicating that this model of iPSC
chondrogenesis replicates many of the features of native cartilage.
In this respect, such in vitro model systems can be used to uncover
key characteristics of the circadian clock development throughout
chondrogenesis and in response to inflammatory cytokines that drive
disease progression. This approach can be expanded to other iPSC
differentiation lineages and additional stimuli to further understand
the circadian clock in development.
Although it is clear that the circadian clock plays a critical role in
articular cartilage physiology and OA pathology, the mechanisms
by which clock genes maintain chondrocyte homeostasis remain to
be determined. Here, we showed different responses of the circadian clock to cytokines in cartilage. By examining the effect of
pathophysiologic concentrations (49) of the cytokines IL-1 and
TNF on the circadian clock as well as the cartilage ECM- and
inflammation-associated genes, we determine that cytokines, IL1 and IL-1, that lead to matrix degradation and up-regulation of
other proinflammatory cytokines such as Il6 drive the disruption in
the circadian clock instead of cytokines such as TNF that had no

effect on the circadian clock, matrix degradation, or up-regulation
of Il6. The difference between the effect of TNF and IL-1 on daily
rhythms has previously been attributed to the activation of NF-B
signaling pathway by IL-1 and lack of activation by TNF (30). In
addition, the loss in ECM components in pellets treated with IL-1
but not TNF suggests that pathways activated by IL-1 leading to
matrix degradation could also be driving the loss of daily rhythms,
which, in turn, exacerbates matrix loss. As observed in cartilage
treated with cytokine (30), the rapid damping of PER2 rhythmicity
could be due to a reduction in the fraction of circadian cells or
synchrony among rhythmic cells. Single-cell imaging could test the
hypothesis that the treatment decreases both the fraction of circadian
cells and synchrony among the cells. This information and this
model system to test cytokines will help elucidate what each cytokine
is directly acting on and help us uncover the direct link between
inflammatory cytokines and the circadian clock.
An interesting observation made throughout this study was the
maintenance of the circadian rhythms in cartilage explants, porcine
chondrocytes, and tissue-engineered cartilage pellets over many days,
where cells or tissues lack exogenous entrainment cues (50). Multiday recordings of adult mouse cartilage explants showed that oscillations were maintained for over 10 days without any perturbations
such as media changes or plate movement. This type of maintained
circadian clock is not common in tissue explants and highlights a
potential interesting area of study (51, 52). While several previous
studies have characterized the chondrocyte circadian clock and its
influence on joint homeostasis, it is not known how the chondrocytes maintain their circadian clock within articular cartilage. It is
hypothesized that changes in body temperature and factors within
the synovial fluid help with clock synchronization (1, 9), but the
prolonged maintenance of the circadian clock ex vivo without any
synchronizing cues highlights that there might be a factor secreted
by the chondrocytes themselves that maintains this synchrony, or
the abundant ECM maintains the biochemical and biomechanical
niche for synchrony (53). Future work looking into potential synchronizing factors will be key in uncovering this mechanism.
The ability of our genetic engineering approaches to maintain the
circadian clock also opens a different area of therapeutic development. There are many diseases that are associated with disruptions
in the circadian clock (2, 4, 7, 8). Using gene therapy approaches to
create cell therapies that focus on preserving or synchronizing the
clock can be a useful arsenal to help ameliorate diseases beyond
OA. For example, in the context of clock preservation in the presence of inflammation, these circuits can be used to protect other
musculoskeletal tissues subject to disease through IL-1–induced inflammation such as the intervertebral disc, which shows similar circadian rhythms and cytokine sensitivity as articular cartilage (2, 54).
Using tissue engineering and creating cells that are capable of maintaining the circadian rhythm, beyond inflammation-driven circuits,
opens the possibility of developing additional engineered cellular
therapeutics against other conditions, such as age-related clock
dampening or cancer (55, 56), through maintenance of the circadian clock and associated genes involved in tissue homeostasis (4, 9).
Using an engineered tissue that can protect itself against inflammation and preserving the circadian clock in response to inflammation can overcome the current limitations in OA therapies and articular
cartilage repair. This work can be expanded to create clock-preserving
cell therapies across many tissues by differentiating already developed
iPSC lines into other tissues or using lentiviral approaches. For
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example, the NFBr-IL1Ra lentiviral system has been used in both
miPSCs and primary porcine chondrocytes for inflammation-activated
and mechanoresponsive drug delivery (44, 45). Future work in comparing rhythmic transcriptomes and understanding the beneficial
effects of rhythm preservation will additionally help further insights
into the physiology of the cartilage clock. This approach opens an
innovative frontier for creating cell-based therapies to maintain the
circadian clock. Together, this framework for developing clockpreserving cell systems provides a new self-regulating approach to
establish therapeutics and enhance tissue repair.
MATERIALS AND METHODS
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Circadian reporter design
Two luciferase reporter lentiviral vectors, one driven by the murine
Bmal1 promoter (Addgene no. 182761) and one driven by the murine
Period 2 (Per2) promoter (Addgene no. 182762), were used (54). These
cassettes result in luciferase expression when the circadian promoters Bmal1 (B1L) and Per2 (P2L) are activated (20). These plasmids
may be obtained by contacting the corresponding author. Bioluminescent reporters of core clock gene transcription are commonly
used in the field of circadian biology to measure phase, period, and
amplitude of rhythms in clock gene expression in real time.
Development of inflammation-resistant and
self-regulating iPSCs
Three different cellular engineering approaches were used to test
the ability to maintain the circadian clock in response to inflammatory cytokine IL-1: A KO miPSC line lacking the IL1R1 (IL1R1
KO) (42), a CRISPR-Cas9–edited miPSC line that incorporates
IL-1Ra downstream of the Ccl2 promoter (Ccl2-IL1Ra) (43), and
cells transduced with a lentiviral gene therapy that includes a synthetic promoter activated by the NF-B pathway that drives IL-1Ra
production (NFBr-IL1Ra) (44). IL1R1 KO–, Ccl2-IL1Ra–, and NFBrIL1Ra–transduced PDiPSCs were all transduced with P2L lentivirus
and pelleted to grow into tissue-engineered cartilage for experimentation. These cell lines may be obtained by contacting the corresponding author.
IL1R1 KO miPSC line
The IL1R1 KO line was created using CRISPR-Cas9 technology
to create a homozygous deletion of the IL1R1. Targeting sequences
flanking exon 2 of Il1r1 and corresponding to 5′-gcttctgtgttgaagactca-3′
and 5′-gtagctgtgggcccacaacc-3′ were selected to generate the deletion
of the IL1r1 signal peptide sequences. To produce single chimeric
guide RNA (gRNA) expression vectors, complementary oligonucleotides containing each of the target sequences were cloned into an
expression vector (Addgene plasmid no. 47108) (60). A plasmid
encoding human codon optimized Streptococcus pyogenes Cas9 (hCas9)
was also obtained from Addgene (plasmid no. 41815) (61). iPSCs were
transfected using Lipofectamine 2000 (Life Technologies) following the
manufacturer’s instructions to cotransfect gRNA plasmids and hCas9
plasmid. Posttransfection cells were subject to single-cell deposition
and were screened for the appropriate deletion via genomic polymerase
chain reaction (PCR). These cells do not respond to the presence of
IL-1 and have been previously shown to be effective in mitigating
inflammation-induced degradation of tissue-engineered cartilage (42).
Ccl2-IL1Ra miPSC line
The Ccl2-IL1Ra line was created using CRISPR-Cas9 technology to
insert IL-1Ra downstream of the Ccl2 promoter, creating a heterozygous cell line. The hCas9 plasmid used in this cell line is the same as
the plasmid used to create the IL1R1 KO line (Addgene no. 41815)
(61). To target hCas9 to the Ccl2 locus, we used a gRNA targeting the
start codon of the Ccl2 coding sequence using the complimentary
oligonucleotides sgMcp1-4_S: 5′-caccGCTCTTCCTCCACCACCATGC-3′
and sgMcp1-4_AS: 5′-aaacGCATGGTGGTGGAGGAAGAGC-3′,
where lowercase bases were used to clone into Bbs I–generated
overhands in the expression vector (Addgene plasmid no. 47108)
(60). Using the same protocol as for the IL1R1 KO line, iPSCs were
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Cell culture and differentiation
Murine-induced pluripotent stem cells
miPSCs, derived from tail fibroblasts from adult C57BL/6 mice and
validated for pluripotency as described in (57, 58), were cultured in
Dulbecco’s modified Eagle’s medium high glucose (DMEM-HG;
Gibco), 20% lot selected fetal bovine serum (FBS; Atlanta Biologicals),
100 nM minimum essential medium nonessential amino acids
(NEAA; Gibco), 55 M 2-mercaptoethanol (2-me; Gibco), gentamicin
(24 ng/ml; Gibco), and mouse leukemia inhibitory factor (LIF;
1000 U/ml; Millipore), and maintained on mitomycin C–treated mouse
embryonic fibroblasts (Millipore).
miPSCs were differentiated toward a mesenchymal state using a
high-density micromass culture (58). Differentiation medium contained DMEM-HG; 1% culture medium supplement containing
recombinant human insulin, human transferrin, and sodium selenite (ITS+, Corning); 100 nM NEAA; 55 M 2-me; gentamicin
(24 ng/ml); l-ascorbic acid (50 g/ml); and l-proline (40 g/ml).
On days 3 to 5, this medium was supplemented with 100 nM dex and
bone morphogenetic protein 4 (BMP-4; 50 ng/ml; R&D Systems).
After 15 days of culture, the micromasses were dissociated with
pronase (MilliporeSigma) and collagenase type II (Worthington
Biochemical), and the PDiPSCs were plated on gelatin-coated dishes
in expansion medium containing DMEM-HG, 10% lot-selected FBS,
1% ITS+, 100 nM NEAA, 55 M 2-me, 1% penicillin/streptomycin
(P/S; Gibco), l-ascorbic acid (50 g/ml), l-proline (40 g/ml), and
basic fibroblast growth factor (bFGF; 4 ng/ml; R&D Systems). To
create a 3D PDiPSC system, passage 2 PDiPSCs were cast in agarose
(4% molten type VII agarose; Sigma-Aldrich) at a final density of
100 million cells/ml in 1% agarose (58).
To create tissue-engineered cartilage, passage 2 PDiPSCs were
pelleted by centrifugation of 250,000 cells (58). Pellets were cultured
for 14 to 21 days in chondrogenic medium consisting of DMEMHG, 1% ITS+, 100 nM NEAA, 55 M 2-me, 1% P/S, l-ascorbic acid
(50 g/ml), l-proline (40 g/ml), 100 nM dex, and transforming growth
factor–3 (TGF-3; 10 ng/ml; R&D Systems).
Porcine primary chondrocytes
Full-thickness porcine articular chondrocytes were enzymatically
isolated using collagenase II (Worthington Biochemical) from the
femurs of pigs obtained from a local abattoir (~30 kg, 12 to 16 weeks
old) postmortem in accordance with an exemption protocol by the
Institutional Animal Care and Use Committee. Filtered cells were
mixed 1:1 with 4% molten type VII agarose (Sigma-Aldrich), and the
cell-agarose mixture was injected into a gel apparatus and allowed
to set at room temperature. Chondrocyte-laden disks were punched
out yielding engineered cartilage at a final concentration of 2% agarose and 15 to 20 million cells/ml. All constructs were cultured in

chondrogenic medium for 2 to 21 days containing DMEM-HG,
10% FBS (Atlas Biologicals), 100 nM NEAA, 15 mM Hepes (Gibco),
l-ascorbic acid (50 g/ml), l-proline (40 g/ml), and 1% P/S (59).
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Lentivirus production and cell transduction
Human embryonic kidney 293T cells were cotransfected with secondgeneration packaging plasmid psPAX2 (no. 12260, Addgene), the
envelope plasmid pMD2.G (no. 12259, Addgene), and the expression transfer vector (B1L, P2L, or NFBr-IL1Ra plasmids) by calcium
phosphate precipitation to make vesicular stomatitis virus glycoprotein pseudotyped lentivirus (64). The lentivirus was harvested
at 24 and 48 hours after transfection and stored at −80°C until use.
The functional titer of the virus was determined with quantitative
real-time PCR to determine the number of lentiviral DNA copies
integrated into the genome of transduced HeLa cells (64). For all
cell transductions, virus was thawed on ice and diluted in medium
to obtain the desired number of viral particles to achieve a multiplicity
of infection of 3 (44). Polybrene was added to a concentration of
4 g/ml to aid in transduction. The medium of the cells was aspirated
and replaced with virus-containing medium, and cells were incubated
for 24 hours before aspirating the viral medium.
Circadian clock characterization through bioluminescence
recordings and imaging
miPSCs and PDiPSCs were transduced with either B1L or P2L virus. PDiPSCs were either cultured in monolayer, cast in agarose, or
pelleted. miPSCs, PDiPSCs, PDiPSCs freshly cast in agarose (PDiPSC
agarose), and mature pellets (tissue-engineered cartilage pellets)
were plated in 35-mm petri dishes with 1 ml of recording medium
containing d-luciferin (GoldBio), sealed with vacuum grease, and
placed in a light-tight 36° incubator containing photomultiplier
tubes (PMTs) (Hamamatsu Photonics). Each dish was placed under
one PMT, and the bioluminescence was recorded as photons per
180 s. Bioluminescence data were detrended with a 24-hour moving
average and analyzed in Chronostar 1.0 (65). Recoding medium
contained DMEM powder (Sigma-Aldrich), B27 supplement (Invitrogen), P/S, l-glutamine (Invitrogen), Hepes (Sigma-Aldrich), and
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d-glucose

(Invitrogen). Porcine chondrocytes were also transduced
with P2L, cast in agarose, cultured, and then subjected to bioluminescence recordings in the dark incubator. As a control, the femoral
head from 10-week-old PER2::LUC reporter mice (founders provided
by J. Takahashi, University of Texas Southwestern) (5) was obtained,
and the bioluminescent output from the cartilage explants was also
recorded. In addition, dishes with pellets in recording media were
recorded for 72 hours using an Andor iKon-M electron-multiplying
charge-coupled device (Oxford Instruments) at a magnification
of ×20 with 1-hour exposures and 2 × 2 binning. During multiday
recordings, samples were maintained at 36° in darkness. Image sequences were concatenated into videos using ImageJ.

Inflammatory challenge and bioluminescence recordings
After 14 days of chondrogenic culture, pellets transduced with P2L
underwent inflammatory challenge with TNF (20 ng/ml), IL-1
(1 ng/ml), IL-1 (1 ng/ml), or a PBS control. Pellets were placed in
recording medium, and bioluminescence was recorded for 72 hours.
After 72 hours of recording, cytokine or PBS was added to the dish,
and bioluminescence was recorded for an additional 72 hours. Pellets
with a period of bioluminescence 18 to 32 hours, mean bioluminescence >30,000 photons, and precytokine cosine fit coefficient of
determination (R2) value >0.8 were included in analysis. This led to
the inclusion of 59 of the 60 pellets recorded for cytokine experiments. Damping is the normally occurring decrease in amplitude
over time in the absence of entraining cues. The change in amplitude
due to treatment was quantified by measuring the absolute difference in peak-trough amplitude 24 hours before and 48 hours following treatment. Additional pellets were treated with cytokines or
PBS and stored at −80°C for quantitative reverse transcription PCR
(qRT-PCR), −20°C for biochemical analysis, or fixed in 10% neutral
buffered formalin (NBF). As a comparison, Per2::Luc mouse femoral
head articular cartilage was dissected from 4- to 6-week-old mice.
The cartilage explants were cultured in DMEM/F12 (without phenol
red and FBS, with l-glutamine and NEAA). Explants were synchronized by 1 hour of treatment with 100 nM dex, and their bioluminescence was recorded in Lumicycle as described previously (18).
Thirty-six hours after synchronization, explants underwent inflammatory challenge with TNF (20 ng/ml), IL-1 (1 ng/ml), IL-1
(1 ng/ml), or a PBS control. After 48 hours of exposure to cytokines,
100 nM dex was added to the medium, and bioluminescence was
recorded for another 48 hours. Damping of the circadian clock was
assessed by measuring of the amplitude of peak before and after
cytokine treatment, before the addition of dex. Explant bioluminescence was normalized by setting the minimum value of the trace to 0
and dividing all values by the maximum value of the trace, making the
maximum value equal to 100%. IL1R1 KO, Ccl2-IL1Ra, NFBr-IL1Ra,
and P2L control pellets were all subjected to inflammatory challenge with IL-1 (1 ng/ml) or a PBS control. Bioluminescence was
recorded 72 hours before addition of cytokine and for 72 hours after
addition of cytokine. Additional pellets were treated with cytokines
or PBS, media were collected, and pellets were stored at −80°C for
qRT-PCR, −20°C for biochemical analysis, or fixed in 10% NBF.
Histological and biochemical analysis of pellet cultures
After 72 hours of inflammatory challenge, pellets were washed with
PBS and fixed in 10% NBF for 24 hours, paraffin embedded, and
sectioned at 8-m thickness. Slides were stained for safranin O/
hematoxylin/fast green (66).
9 of 11

Downloaded from https://www.science.org at Washington University on June 05, 2022

transfected using Lipofectamine 2000 (Life Technologies), and cells
were subjected to single-cell deposition. Clones were screened via
genomic PCR. Ccl2 is a common gene up-regulated with inflammation in cartilage, and therefore, the Ccl2-IL1Ra cells effectively sense
inflammation and produce an anti-inflammatory therapeutic in an
autoregulated manner (43).
NFBr-IL1Ra lentiviral vector
To create the NFBr-IL1Ra lentiviral vector, a synthetic NF-B–
inducible promoter was designed to incorporate multiple NF-B
response elements as previously described (Addgene no. 183065)
(44). A synthetic promoter was developed containing five consensus sequences approximating the NF-B canonical recognition motif based on genes up-regulated through inflammatory challenge:
InfB1, Il6, Mcp1, Adamts5, and Cxcl10. The specific sequence cloned
was 5′-CGGGAATTCCGCTAGCACTAGTGGGACTTTCCCACTAGTGGGAAATTAGCCCGGGACTTTCCCGTCTCCTCGAGGGGACTTCCCA-3′. A TATA box derived from the minimal
cytomegalovirus promoter was cloned between the synthetic promoter and downstream target gene, murine Il1rn, and an NF-B–
negative regulatory element (NRE-5′-AATTCCTCTGA-3′) was cloned
upstream of the promoter to reduce background signal (44, 62, 63).
This lentiviral vector was developed in our lab and has been shown
to protect tissue-engineered cartilage from inflammation-mediated
degradation and to be mechanoresponsive and used in porcine tissue–
engineered cartilage (44, 45).
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For biochemical analysis, pellets were digested overnight in
papain (125 g/ml) at 65°C. DNA content was measured with
PicoGreen assay (Thermo Fisher Scientific), and total sGAG content
was measured using a 1,9-dimethylmethylene blue assay at 525-nm
wavelength (67).

Enzyme-linked immunosorbent assays
After 72 hours of inflammatory challenge, culture media were collected from pellets and stored at −20°C. IL-1Ra concentration was
measured with DuoSet enzyme-linked immunosorbent assay (ELISA)
specific to mouse IL-1Ra/IL-1F3 (R&D Systems).
Statistical analysis
Statistical analysis was performed using Prism. A one-way analysis
of variance (ANOVA) with Dunnett’s post hoc test was used to analyze all biochemistry data for P2L pellets given TNF, IL-1, IL-1,
or PBS with PBS as the control ( = 0.05). A one-way ANOVA was
used to analyze change in amplitude for pellets given TNF-, IL-1,
IL-1, or PBS with PBS as the control ( = 0.05). In addition, a oneway ANOVA with Dunnett’s post hoc test was used to analyze biochemistry data for IL1R1 KO, Ccl2-IL1Ra, and NFBr-IL1Ra pellet
experiments within each group with 0 ng/ml dose as the control
( = 0.05). A two-way ANOVA with Tukey’s post hoc test was used
to analyze all qRT-PCR data and the ELISA data for IL1R1 KO,
Ccl2-IL1Ra, and NFBr-IL1Ra pellet experiments ( = 0.05). Statistical analysis for cartilage explants and their response to inflammatory cytokines was performed using a one-way ANOVA comparing
the values of the peak after control or cytokine treatment.
SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at https://science.org/doi/10.1126/
sciadv.abj8892
View/request a protocol for this paper from Bio-protocol.
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